Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 05 tags : Trial save search
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Published: 2022-05-05 (Crawled : 20:00) - biospace.com/
ODYY | $0.0337 500
|
Manufacturing
|
| O: 28.45%
H: 0.0%
C: -32.76%
drug trial positive
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
Published: 2022-05-05 (Crawled : 18:00) - biospace.com/
AMLX | $1.985 0.25% 270K
|
|
| O: -0.79%
H: 1.1%
C: -7.57%
amx0035 als trial publication
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 16:00) - globenewswire.com
ZLAB | News | $14.125 -0.67% 45K
|
Health Technology
|
| O: -1.73%
H: 0.38%
C: -3.24%
ARGX | $360.47 0.58% 45K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Riskified Ltd. (RSKD) Investors with Significant Losses to Contact Firm's Attorneys, IPO-Related Securities Class Action Filed
Published: 2022-05-05 (Crawled : 14:00) - prnewswire.com
RSKD | $4.975 1.12% 57K
|
|
| O: 3.12%
H: 0.16%
C: -5.86%
trial
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
Published: 2022-05-05 (Crawled : 13:20) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -1.28%
H: 0.0%
C: -2.48%
pnt2002 biopharma trial
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
PALI | $4.62 -8.88% 68K
|
Manufacturing
|
| O: -2.21%
H: 7.35%
C: 4.49%
lb1148 clearance trial china phase 3
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.255 0.72% 200K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: -1.16%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
ARCT 4 | $26.305 -0.06% 65K
|
Health Technology
|
| O: 6.93%
H: 1.13%
C: -8.47%
arct-154 trial results
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
ALZN | $0.6999 1.29% 3.4K
|
Professional, Scientific, and T...
|
| O: 3.52%
H: 4.85%
C: 2.91%
al001 treatment dementia trial alzheimer’s alzheimer's
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
Published: 2022-05-05 (Crawled : 12:20) - biospace.com/
MRNS | $1.465 3.9% 910K
|
Health Technology
|
| O: -2.66%
H: 1.29%
C: -2.42%
epilepticus trial phase 3
Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
Published: 2022-05-05 (Crawled : 11:00) - biospace.com/
IMUX | $1.25 -1.58% 37K
|
Health Technology
|
| O: -1.74%
H: 0.0%
C: -8.1%
imu-856 disease trial phase 1
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
ARGX | $360.47 0.58% 45K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate
Published: 2022-05-05 (Crawled : 09:00) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
covid-19 vaccine trial phase 2
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.